Bevacizumab in ovarian cancer: A critical review of phase III studies

被引：93

作者：

Rossi, Luigi ^{[1
]}

Verrico, Monica ^{[1
]}

Zaccarelli, Eleonora ^{[1
]}

Papa, Anselmo ^{[1
]}

Colonna, Maria ^{[2
]}

Strudel, Martina ^{[1
]}

Vici, Patrizia ^{[3
]}

Bianco, Vincenzo ^{[5
]}

Tomao, Federica ^{[4
]}

机构：

[1] Sapienza Univ Rome, ICOT, Dept Medsurg Sci & Biotechnol, Oncol Unit, Latina, Italy

[2] Dono Svizzero Hosp, Oncol Unit, Formia, Italy

[3] Regina Elena Inst Canc Res, Div Med Oncol 2, Rome, Italy

[4] Sapienza Univ Rome, Policlin Umberto 1, Dept Obstet & Gynaecol, Rome, Italy

[5] Sapienza Univ Rome, Policlin Umberto 1, Div Med Oncol, Rome, Italy

来源：

ONCOTARGET | 2017年 / 8卷 / 07期

关键词：

ovarian cancer; bevacizumab; biological therapy; anti-angiogenic therapy; chemotherapy; PEGYLATED LIPOSOMAL DOXORUBICIN; ADVANCED EPITHELIAL OVARIAN; PRIMARY PERITONEAL CANCER; COST-EFFECTIVENESS; OPEN-LABEL; STANDARD CHEMOTHERAPY; 1ST-LINE TREATMENT; TUMOR VASCULATURE; PACLITAXEL; TRIAL;

D O I：

10.18632/oncotarget.13310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line treatment of advanced OC and for platinum-sensitive and platinum-resistant recurrent OC. These trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, BV effectively improved the quality of life with regard to abdominal symptoms in recurrent OC patients. Bevacizumab is associated with adverse events such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed. This review describes the latest evidence for BV treatment of OC and selection of patients for personalized treatment.

引用

页码：12389 / 12405

页数：17

共 76 条

[1] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer [J].

Aghajanian, Carol ;

Goff, Barbara ;

Nycum, Lawrence R. ;

Wang, Yan V. ;

Husain, Amreen ;

Blank, Stephanie V. .

GYNECOLOGIC ONCOLOGY, 2015, 139 (01) :10-16

[2] Cancer prevention by targeting angiogenesis [J].

Albini, Adriana ;

Tosetti, Francesca ;

Li, Vincent W. ;

Noonan, Douglas M. ;

Li, William W. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (09) :498-509

[3] New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential [J].

Banerjee, Susana ;

Kaye, Stanley B. .

CLINICAL CANCER RESEARCH, 2013, 19 (05) :961-968

[4] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer [J].

Barnett, Jason C. ;

Secord, Angeles Alvarez ;

Cohn, David E. ;

Leath, Charles A., III ;

Myers, Evan R. ;

Havrilesky, Laura J. .

CANCER, 2013, 119 (20) :3653-3661

[5]

Basen-Engquist K, ASCO 2015 CHIC IL

[6] Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms [J].

Bellati, Filippo ;

Napoletano, Chiara ;

Gasparri, Maria Luisa ;

Ruscito, Ilary ;

Marchetti, Claudia ;

Pignata, Sandro ;

Tomao, Federica ;

Panici, Pierluigi Benedetti ;

Nuti, Marianna .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (01) :35-46

[7] Cost-effectiveness analysis of paclitaxel acid cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective [J].

Berger, K ;

Fischer, T ;

Szucs, TD .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) :1894-1901

[8] Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms [J].

Bidus, Michael A. ;

Webb, Joel C. ;

Seidman, Jeffrey D. ;

Rose, G. Scott ;

Boice, Charles R. ;

Elkas, John C. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (01) :5-7

[9] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].

Bookman, MA ;

Darcy, KM ;

Clarke-Pearson, D ;

Boothby, RA ;

Horowitz, IR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290

[10] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].

Bookman, Michael A. ;

Brady, Mark F. ;

McGuire, William P. ;

Harper, Peter G. ;

Alberts, David S. ;

Friedlander, Michael ;

Colombo, Nicoletta ;

Fowler, Jeffrey M. ;

Argenta, Peter A. ;

De Geest, Koen ;

Mutch, David G. ;

Burger, Robert A. ;

Swart, Ann Marie ;

Trimble, Edward L. ;

Accario-Winslow, Chrisann ;

Roth, Lawrence M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425

← 1 2 3 4 5 6 7 8 →